sprng23 / iStockphoto.com
A Biogen patent covering the drug Tecfidera (dimethyl fumarate) has been upheld by the Patent Trial and Appeal Board (PTAB), after a challenge from Kyle Bass’s Coalition for Affordable Drugs.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
PTAB, Biogen, IPR, inter partes review, USPTO, Kyle Bass, Coalition for Affordable Drugs, multiple sclerosis, Tecfidera, patent
